Polycystic ovary syndrome through the prism of cardiometabolic risk: From pathogenesis to new therapeutic strategies
- 3 May 2026
- journal article
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 7 (1) , 66-75
Abstract
Polycystic ovary syndrome (PCOS) is considered a complex multisystem condition with a pronounced cardiometabolic profile in modern medicine. Traditional therapeutic strategies based on combined oral contraceptives and metformin are often insufficiently effective for long-term correction of metabolic risks and prevention of cardiovascular complications. This article discusses the paradigm shift in PCOS treatment, favoring the use of incretin agents – GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide). The multifaceted mechanism of action of these agents is analyzed, including not only weight loss and insulin resistance but also a direct impact on the pathophysiological components of the disease: hyperandrogenism, systemic inflammation, and ovarian dysfunction. The paper presents data from recent meta-analyses confirming significant improvements in anthropometric parameters and lipid profiles in PCOS under the influence of incretins. Integrating incretin therapy into PCOS management algorithms opens new possibilities for comprehensive metabolic and reproductive rehabilitation of patients, providing a personalized approach to the treatment of this heterogeneous disease.Keywords
This publication has 34 references indexed in Scilit:
- Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patientsGynecological Endocrinology, 2025
- Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trialsScientific Reports, 2025
- Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomesAmerican Journal of Obstetrics and Gynecology, 2025
- Definition and diagnostic criteria of clinical obesityThe Lancet Diabetes & Endocrinology, 2025
- Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapyNature Communications, 2024
- The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trialsJournal of Diabetes and its Complications, 2024
- Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease preventionTrends in Cardiovascular Medicine, 2020
- Polycystic ovary syndrome: definition, aetiology, diagnosis and treatmentNature Reviews Endocrinology, 2018
- Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trialReproductive BioMedicine Online, 2017
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndromeFertility and Sterility, 2004